Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dura mater guidance

This article was originally published in The Gray Sheet

Executive Summary

Comments are due Jan. 12, 2000 on the agency's draft "Guidance for the Preparation of a Premarket Notification Application for Processed Human Dura Mater," one of several special controls cited by the Neurological Devices Panel in its Sept. 16 recommendation to classify processed human dura mater as a Class II device (1"The Gray Sheet," Sept. 20, p. 6). Last revised in August, the document addresses product characterization, specifications, manufacturing controls, and labeling issues

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel